title: Acute and long-term effects of enalapril on the cardiovascular response to exercise and exercise tolerance in patients with congestive heart failure.
abstract: Enalapril is a recently developed angiotensin-converting enzyme inhibitor that improves cardiac function at rest in patients with congestive heart failure. This study investigated the acute effects of enalapril on the cardiovascular response to exercise, and then evaluated the long-term effects of enalapril on exercise capacity and functional status during a 12 week placebo-controlled trial in patients with heart failure. Ten patients underwent hemodynamic monitoring while at rest and during incremental bicycle exercise before and after 5 to 10 mg of enalapril orally. At rest, enalapril decreased mean blood pressure 13% (p less than 0.01) and systemic vascular resistance 20% (p less than 0.05) and increased stroke volume index 21% (p less than 0.01). During maximal exercise, enalapril decreased systemic vascular resistance and increased both cardiac and stroke volume indexes. Enalapril acutely increased exercise duration (p less than 0.05) and maximal oxygen consumption (p less than 0.001). These 10 patients and an additional 13 patients were then randomized to either placebo or enalapril treatment and followed up for 12 weeks. Of the 11 patients assigned to active treatment, 73% considered themselves improved compared with 25% of the patients assigned to placebo treatment (p less than 0.02). During long-term treatment, exercise capacity increased in patients receiving enalapril (p less than 0.001) but was unchanged in patients receiving placebo (intergroup difference, p less than 0.05). During long-term treatment, no adverse effects of enalapril occurred. Thus, enalapril improves cardiac function at rest and during exercise. Compared with placebo, maintenance therapy with enalapril results in symptomatic improvement and increased exercise capacity.
authors.forename: M A
authors.initials: MA
authors.lastname: Creager
authors.forename: B M
authors.initials: BM
authors.lastname: Massie
authors.forename: D P
authors.initials: DP
authors.lastname: Faxon
authors.forename: S D
authors.initials: SD
authors.lastname: Friedman
authors.forename: B L
authors.initials: BL
authors.lastname: Kramer
authors.forename: D A
authors.initials: DA
authors.lastname: Weiner
authors.forename: T J
authors.initials: TJ
authors.lastname: Ryan
authors.forename: N
authors.initials: N
authors.lastname: Topic
authors.forename: C D
authors.initials: CD
authors.lastname: Melidossian
mesh_terms: D000328:Adult; D000368:Aged; D002319:Cardiovascular System / Q000187:drug effects* / Q000503:physiopathology; D004151:Dipeptides / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D004656:Enalapril; D005500:Follow-Up Studies; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008875:Middle Aged; D010101:Oxygen Consumption / Q000187:drug effects; D005082:Physical Exertion; D012083:Renin / Q000097:blood; D013318:Stroke Volume / Q000187:drug effects; D013997:Time Factors
chemical_list: D004151:Dipeptides; D004656:Enalapril; D012083:Renin